Contents

Search


angiotensin receptor neprilysin inhibitor (ARNI)

Indications: - systolic heart failure Containdications: - diastolic heart failure [3] - use in combination with ACE inhibitor or ARB Adverse effects: - increases serum BNP (but decreases serum NT-proBNP) [2]

Interactions

drug interactions

Specific

sacubitril/valsartan (Entresto)

General

pharmacologic combination

References

  1. AGS Member Forum. May 28, 2018 The latest ACC/AHA/HFSA recommendations for Stage C HFrEF
  2. Velazquez EJ, Morrow DA, DeVore AD et al. PIONEER-HF Investigators Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2018 Nov 11. PMID: 30415601 https://www.nejm.org/doi/10.1056/NEJMoa1812851
  3. Solomon SD, McMurray JJV, Anand IS et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019 Sep 1; PMID: 31475794 https://www.nejm.org/doi/10.1056/NEJMoa1908655

Components

angiotensin II receptor antagonist (ARB) neprilysin inhibitor